TXG Stock Price Today (October 2026) — 10x Genomics, Inc. Analysis & Key Metrics 2026-10-23
10x Genomics, Inc. (TXG) is trading at $71.55, up 2.58% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $77.50 (8.3% upside).
- Volatility is high (89.38% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-12.70% YoY) alongside competitive pressures in the Medical Devices space.
TXG Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
10x Genomics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $8.85B
P/E Ratio
Forward P/E: 933.22
Revenue Growth
Year over Year
Analyst Target
+8.3% upside potential
Key Investor Questions About TXG
What investors need to know before buying
Based on current market data, TXG presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 43.57)
- Fundamentals say: Challenging (declining revenue trends)
TXG's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TXG investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $78.80M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, TXG stock traded between $12.34 and $102.81 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 89.38% annualized volatility and β=2.32, the stock exhibits high sensitivity to market moves—making TXG suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
1 unprofitable stock with exciting potential and 2 that underwhelm
Stephens Downgrades 10x Genomics to Equal Weight From Overweight, $65 Price Target
3 Healthcare Stocks That Concern Us
10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand
3 Reasons to Sell TXG and 1 Stock to Buy Instead
Latest TickZen Insights
All insights →No TickZen article on TXG yet. Our newest analysis:
Explore More Analysis for TXG
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (after the close)
Frequently Asked Questions
Common investor questions about 10x Genomics, Inc.
10x Genomics, Inc. (TXG) is currently trading at $71.55. The RSI (14-day) is at 43.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $77.50 implies 8.3% upside from current levels. Volatility is high at 89.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for 10x Genomics, Inc. (TXG): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 933.22. Price-to-Book is 11.29. Price-to-Sales is 15.11. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering TXG, the consensus price target is $77.50. This represents a 8.3% upside from the current price of $71.55. The range spans from a low target of $50.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
10x Genomics, Inc. (TXG) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for 10x Genomics, Inc. (TXG) investors include: 1. High volatility (89.4% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-12.7% YoY), indicating potential business headwinds. 4. Elevated short interest (17.3% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is 10x Genomics, Inc.'s (TXG) current debt and financial health profile: Total debt stands at $78.80M. The debt-to-equity ratio is 0.10x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.69, indicating strong short-term liquidity. The quick ratio is 5.09. The company holds $552.03M in cash and equivalents. Free cash flow is positive at $121.44M, providing a cushion for debt servicing and shareholder returns.